Coherus Aiming For More Than 10% Slice Of US Adalimumab Market

US-Based Firm Has December 2021 FDA Goal Date

 
• By Dean Rudge

Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.

Growth Strategy on Mechanism of Golden Metallic Gears. Growth Strategy on the Mechanism of Golden Cogwheels with Lens Flare. Growth Strategy - Illustration with Glowing Light Effect.
Coherus believes its customer-focused approach will stand it in good stead for the multi-billion-dollar adalimumab market • Source: Shutterstock

More from Biosimilars

More from Products